SCHEMBL1343902

SCHEMBL1343902

CCOC(=O)c1[nH]c2ccc(OC)cc2c1CCCNC(=O)OC(C)(C)C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 1/20 0.69
MTNR1A P48039 9/20 0.60
MTNR1B P49286 9/20 0.60
ALDH1A1 P00352 8/20 0.57
KDM4E B2RXH2 6/20 0.57
HPGD P15428 5/20 0.57
MAPT P10636 2/20 0.57
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
HSD17B10 Q99714 5/20 0.57
LMNA P02545 2/20 0.57
HTT P42858 1/20 0.57
GAA P10253 3/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
POLB P06746 1/20 0.52
MDM2 Q00987 1/20 0.52
CYP1A2 P05177 1/20 0.50
TUBB4A P04350 1/20 0.48
TUBB P07437 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16711696 0.95 NQO2 (0.76) NQO2MTNR1AMTNR1BALDH1A1KDM4E
SCHEMBL1343728 0.89 KDM4E (0.66) NQO2MTNR1AMTNR1BALDH1A1KDM4E
SCHEMBL1345671 0.88 NQO2 (0.52) NQO2MTNR1AMTNR1BALDH1A1KDM4E
SCHEMBL1345946 0.88 NQO2 (0.52) NQO2MTNR1AMTNR1BALDH1A1KDM4E
SCHEMBL1345426 0.87 NQO2 (0.52) NQO2MTNR1AMTNR1BALDH1A1KDM4E
SCHEMBL1345218 0.87 TRPM8 (0.54) NQO2MTNR1AMTNR1BALDH1A1KDM4E
SCHEMBL1343747 0.84 NQO2 (0.48) NQO2MTNR1AMTNR1BALDH1A1KDM4E
SCHEMBL1346372 0.84 NQO2 (0.48) NQO2MTNR1AMTNR1BALDH1A1KDM4E
SCHEMBL16711721 0.83 KDM4E (0.74) NQO2MTNR1AMTNR1BALDH1A1KDM4E
SCHEMBL16926301 0.82 ALDH1A1 (0.59) NQO2MTNR1AMTNR1BALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063094-B2 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-22 US disclosed
US-8063094-B2 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-22 US disclosed
US-8063094-B2 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-22 US disclosed
US-20110053955-A1 ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-03 US disclosed
US-20110053955-A1 ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-03 US disclosed
US-20110053955-A1 ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-03 US disclosed
WO-2008098096-A1 ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-08-14 WO disclosed
WO-2008098096-A1 ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053955-A1 ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS MAPKAPK2, IL2, MAP3K2 NQO2 2489/4885MTNR1A 2127/4885MTNR1B 2150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.